Completed PHASE2 INTERVENTIONAL 4-arm NCT02947724

Surgicel Reduces Ovarian Endometriomas Recurrence

The Use of Surgicel in Preventing Recurrence of Ovarian Endometriomas During Laparoscopic Surgery

Sponsor: Cairo University

Interventions SURGICEL®

Updated 7 times since 2017 Last updated: Apr 12, 2019 Started: Jan 31, 2016 Primary completion: Jan 31, 2019 Completion: Jan 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02947724, this PHASE2 trial focuses on Endometrioma and remains completed. Sponsored by Cairo University, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
May 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jun 2018 — May 2019 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cairo University

Data source: Cairo University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cairo, Egypt